ライフサイエンスコーパス: neuromuscular block

1 pproach to rapidly antagonize deep levels of neuromuscular block.

2 ule rebinds cation and regains catalytic and neuromuscular blocking activity.

3 pertoire [10/44 (23%) lacked BSACI compliant neuromuscular blocking agent (NMBA) panels and 17/44 (39

4 Eleven patients received a neuromuscular blocking agent (NMBA) without a sedative/a

5 xamined the association between receipt of a neuromuscular blocking agent and in-hospital mortality a

6 Whether the type of neuromuscular blocking agent and the duration of use are

7 e-Dawley rats (age 4 months), treated with a neuromuscular blocking agent and ventilated: control, hy

8 an instrumental variable found receipt of a neuromuscular blocking agent associated with a 4.3% (95%

9 ncluding 1,818 (23%) who were treated with a neuromuscular blocking agent by hospital day 2.

10 She is placed in the prone position and a neuromuscular blocking agent is administered, without im

11 espiratory infection, early treatment with a neuromuscular blocking agent is associated with lower in

12 On day 13, neuromuscular blocking agent therapy was discontinued, b

13 n the propensity for treatment, receipt of a neuromuscular blocking agent was associated with a reduc

14 ithout spontaneous breathing (prevented by a neuromuscular blocking agent).

15 ered one or more sedative, analgesic, and/or neuromuscular blocking agent, range 1-9 drugs, mean 2.5

16 neuromuscular blockade: encapsulation of the neuromuscular blocking agent, resulting in inactivation.

17 e adult cats, anaesthetized, injected with a neuromuscular blocking agent, vagotomized and artificial

18 An analysis using the hospital neuromuscular blocking agent-prescribing rate as an inst

19 nts all had ARDS and had been treated with a neuromuscular blocking agent.

20 s that a protocol should include guidance on neuromuscular-blocking agent administration in patients

21 1) We suggest that a neuromuscular-blocking agent be administered by continuo

22 practice suggests that a reduced dose of an neuromuscular-blocking agent be used for patients with m

23 sistent weight over another when calculating neuromuscular-blocking agent doses in obese patients.

24 patients receiving a continuous infusion of neuromuscular-blocking agent receive a structured physio

25 cting rather than long-acting intraoperative neuromuscular blocking agents (1 RCT) reduce risk.

26 studied the ability of four nondepolarizing neuromuscular blocking agents (atracurium, gallamine, me

27 guidelines during use of continuous-infusion neuromuscular blocking agents (NMB) in the intensive car

28 perioperative anaphylaxis but not exposed to neuromuscular blocking agents (NMBA) were included.

29 Anaphylactic reactions to neuromuscular blocking agents (NMBAs) can be severe and

30 e administration of analgesic, sedative, and neuromuscular blocking agents (NMBAs) for each patient.

31 Neuromuscular blocking agents (NMBAs) induce dose-depend

32 Allergy to neuromuscular blocking agents (NMBAs) is the most import

33 The use of sedatives, opioids, and neuromuscular blocking agents (NMBAs) may delay weaning

34 postulated cause of allergic anaphylaxis to neuromuscular blocking agents (NMBAs).

35 o significantly more likely to have received neuromuscular blocking agents (p = .004) or propofol (p

36 Without their use, dosing of neuromuscular blocking agents and anticholinesterases is

37 Long-term treatment with nondepolarizing neuromuscular blocking agents and corticosteroids in the

38 We examined the association between neuromuscular blocking agents and ICU-acquired weakness,

39 The relationship between neuromuscular blocking agents and neuromuscular dysfunct

40 alysis suggests a modest association between neuromuscular blocking agents and neuromuscular dysfunct

41 ed trial did not show an association between neuromuscular blocking agents and neuromuscular dysfunct

42 ndromes were also associated with the use of neuromuscular blocking agents and prolonged mechanical v

43 f an adverse relationship between the use of neuromuscular blocking agents and skeletal muscle weakne

44 Neuromuscular blocking agents are commonly used in criti

45 Neuromuscular blocking agents are routinely used in the

46 d guidelines and protocols could ensure that neuromuscular blocking agents are used and monitored app

47 However, use of neuromuscular blocking agents during emergent airway man

48 Intensivists use neuromuscular blocking agents for a variety of clinical

49 s, 'experts' in the clinical pharmacology of neuromuscular blocking agents have advocated routine int

50 The use of sedatives and neuromuscular blocking agents in the ICU is positively a

51 This includes the injection of neuromuscular blocking agents into anterior scalene musc

52 We hypothesized that the use of neuromuscular blocking agents is associated with a decre

53 Recent trials suggest that treatment with neuromuscular blocking agents may improve survival in pa

54 nsible for ICU-AW and provides evidence that neuromuscular blocking agents may not be a major cause o

55 suggested that some pairs of nondepolarizing neuromuscular blocking agents might be more efficacious

56 er that irrespective of chemical structural, neuromuscular blocking agents might produce prolonged pa

57 his system have the capability to administer neuromuscular blocking agents to facilitate intubation (

58 uscular disease, addiction, epilepsy and for neuromuscular blocking agents used during surgery.

59 ted data included demographics, sedation and neuromuscular blocking agents used, mechanical ventilati

60 The use of neuromuscular blocking agents was associated with a lowe

61 Use of neuromuscular blocking agents was associated with signif

62 nd route of administration for sedatives and neuromuscular blocking agents were abstracted from ICU f

63 Patients who received neuromuscular blocking agents were younger (mean age, 62

64 Total body weight dosing of neuromuscular blocking agents will result in a prolonged

65 ompare the outcomes of patients treated with neuromuscular blocking agents within the first 2 hospita

66 romuscular weakness and included charges for neuromuscular blocking agents, continuous mechanical ven

67 predominant one, along with potentiation by neuromuscular blocking agents, immobilization, and proba

68 modynamic monitoring and use of sedative and neuromuscular blocking agents, more mechanical ventilati

69 requirements for vasopressors, sedatives, or neuromuscular blocking agents, percentage of patients th

70 groups bind tightly to several commonly used neuromuscular blocking agents, such as rocuronium, in aq

71 The use of neuromuscular blocking agents, when used by intensivists

72 he adverse events associated with the use of neuromuscular blocking agents.

73 ght complexes in a 1: 1 ratio with steroidal neuromuscular blocking agents.

74 al, many monitors are affected by the use of neuromuscular blocking agents.

75 igned that selectively encapsulate steroidal neuromuscular blocking agents.

76 ects of combining different non-depolarizing neuromuscular blocking agents.

77 eroids in combination with variable doses of neuromuscular blocking agents.

78 ined after discontinuation of treatment with neuromuscular blocking agents.

79 prescriptions of sedative, analgesic, and/or neuromuscular blocking agents; nurse administration of t

80 10) We suggest that neuromuscular-blocking agents be discontinued at the end

81 6) Optimal clinical practice suggests that neuromuscular-blocking agents be discontinued prior to t

82 ht or adjusted body weight) when calculating neuromuscular-blocking agents doses for obese patients.

83 make no recommendation on the routine use of neuromuscular-blocking agents for patients undergoing th

84 3) We suggest a trial of a neuromuscular-blocking agents in life-threatening situat

85 8) We make no recommendation on the use of neuromuscular-blocking agents in pregnant patients.

86 4) We suggest that neuromuscular-blocking agents may be used to manage over

87 est against the routine administration of an neuromuscular-blocking agents to mechanically ventilated

88 unintended extubation in patients receiving neuromuscular-blocking agents.

89 in patients receiving continuous infusion of neuromuscular-blocking agents.

90 of less than 180 mg/dL in patients receiving neuromuscular-blocking agents.

91 specific to patients receiving infusions of neuromuscular-blocking agents.

92 sedation during continuous administration of neuromuscular-blocking agents.

93 in patients with myasthenia gravis receiving neuromuscular-blocking agents.

94 r patients receiving continuous infusions of neuromuscular-blocking agents.

95 stimulators allows clinicians to administer neuromuscular blocking and reversal agents in a rational

96 itatively by acceleromyography, and residual neuromuscular block be reversed.

97 gitation behaviors; sedative, analgesic, and neuromuscular blocking drug administration; ventilation

98 istically associated with bronchospasm was a neuromuscular blocking drug, with both IgE- or non-IgE-m

99 Sugammadex binds neuromuscular blocking drugs and encapsulates them, maki

100 gammadex is a novel drug that binds selected neuromuscular blocking drugs and prevents them from acti

101 Neuromuscular blocking drugs were introduced into clinic

102 potent reversal agent for rocuronium-induced neuromuscular block in rats.

103 Residual neuromuscular block is a relatively frequent occurrence

104 l studies demonstrating complement-dependent neuromuscular block may be relevant to the clinical path